Albertus W Hensbergen1, Tessa Buckle1, Danny M van Willigen1, Margret Schottelius2, Mick M Welling1, Felicia A van der Wijk1, Tobias Maurer3, Henk G van der Poel4, Gabri van der Pluijm5, Wytske M van Weerden6, Hans-Jürgen Wester2, Fijs W B van Leeuwen7. 1. Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. 2. Pharmazeutische Radiochemie, Technische Universität München, Garching, Germany. 3. Martini-Klinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany. 4. Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. 5. Department of Urology, Leiden University Medical Centre, Leiden, The Netherlands; and. 6. Department of Urology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands. 7. Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands f.w.b.van_leeuwen@lumc.nl.
Abstract
Prostate cancer surgery is currently being revolutionized by the use of prostate-specific membrane antigen (PSMA)-targeted radiotracers, for example, 99mTc-labeled PSMA tracer analogs for radioguided surgery. The purpose of this study was to develop a second-generation 99mTc-labeled PSMA-targeted tracer incorporating a fluorescent dye. Methods: Several PSMA-targeted hybrid tracers were synthesized: glutamic acid-urea-lysine (EuK)-Cy5-mas3, EuK-(SO3)Cy5-mas3, EuK-Cy5(SO3)-mas3, EuK-(Ar)Cy5-mas3, and EuK-Cy5(Ar)-mas3; the Cy5 dye acts as a functional backbone between the EuK targeting vector and the 2-mercaptoacetyl-seryl-seryl-seryl (mas3) chelate to study the dye's interaction with PSMA's amphipathic entrance funnel. The compounds were evaluated for their photophysical and chemical properties and PSMA affinity. After radiolabeling with 99mTc, we performed in vivo SPECT imaging, biodistribution, and fluorescence imaging on BALB/c nude mice with orthotopically transplanted PC346C tumors. Results: The dye composition influenced the photophysical properties (brightness range 0.3-1.5 × 104 M-1 × cm-1), plasma protein interactions (range 85.0% ± 2.3%-90.7% ± 1.3% bound to serum, range 76% ± 0%-89% ± 6% stability in serum), PSMA affinity (half-maximal inhibitory concentration [IC50] range 19.2 ± 5.8-175.3 ± 61.1 nM) and in vivo characteristics (tumor-to-prostate and tumor-to-muscle ratios range 0.02 ± 0.00-154.73 ± 28.48 and 0.46 ± 0.28-5,157.50 ± 949.17, respectively; renal, splenic, and salivary retention). Even though all tracer analogs allowed tumor identification with SPECT and fluorescence imaging, 99mTc-EuK-(SO3)Cy5-mas3 had the most promising properties (e.g., half-maximal inhibitory concentration, 19.2 ± 5.8, tumor-to-muscle ratio, 5,157.50 ± 949.17). Conclusion: Our findings demonstrate the intrinsic integration of a fluorophore in the pharmacophore in PSMA-targeted small-molecule tracers. In this design, having 1 sulfonate on the indole moiety adjacent to EuK (99mTc-EuK-(SO3)Cy5-mas3) yielded the most promising tracer candidate for imaging of PSMA.
Prostate cancer surgery is currently being revolutionized by the use of prostate-specific membrane antigen (PSMA)-targeted radiotracers, for example, 99mTc-labeled PSMA tracer analogs for radioguided surgery. The purpose of this study was to develop a second-generation 99mTc-labeled PSMA-targeted tracer incorporating a fluorescent dye. Methods: Several PSMA-targeted hybrid tracers were synthesized: glutamic acid-urea-lysine (EuK)-Cy5-mas3, EuK-(SO3)Cy5-mas3, EuK-Cy5(SO3)-mas3, EuK-(Ar)Cy5-mas3, and EuK-Cy5(Ar)-mas3; the Cy5 dye acts as a functional backbone between the EuK targeting vector and the 2-mercaptoacetyl-seryl-seryl-seryl (mas3) chelate to study the dye's interaction with PSMA's amphipathic entrance funnel. The compounds were evaluated for their photophysical and chemical properties and PSMA affinity. After radiolabeling with 99mTc, we performed in vivo SPECT imaging, biodistribution, and fluorescence imaging on BALB/c nude mice with orthotopically transplanted PC346C tumors. Results: The dye composition influenced the photophysical properties (brightness range 0.3-1.5 × 104 M-1 × cm-1), plasma protein interactions (range 85.0% ± 2.3%-90.7% ± 1.3% bound to serum, range 76% ± 0%-89% ± 6% stability in serum), PSMA affinity (half-maximal inhibitory concentration [IC50] range 19.2 ± 5.8-175.3 ± 61.1 nM) and in vivo characteristics (tumor-to-prostate and tumor-to-muscle ratios range 0.02 ± 0.00-154.73 ± 28.48 and 0.46 ± 0.28-5,157.50 ± 949.17, respectively; renal, splenic, and salivary retention). Even though all tracer analogs allowed tumor identification with SPECT and fluorescence imaging, 99mTc-EuK-(SO3)Cy5-mas3 had the most promising properties (e.g., half-maximal inhibitory concentration, 19.2 ± 5.8, tumor-to-muscle ratio, 5,157.50 ± 949.17). Conclusion: Our findings demonstrate the intrinsic integration of a fluorophore in the pharmacophore in PSMA-targeted small-molecule tracers. In this design, having 1 sulfonate on the indole moiety adjacent to EuK (99mTc-EuK-(SO3)Cy5-mas3) yielded the most promising tracer candidate for imaging of PSMA.
Authors: Anton Bunschoten; Danny M van Willigen; Tessa Buckle; Nynke S van den Berg; Mick M Welling; Silvia J Spa; Hans-Jürgen Wester; Fijs W B van Leeuwen Journal: Bioconjug Chem Date: 2016-04-28 Impact factor: 4.774
Authors: Danny M van Willigen; Nynke S van den Berg; Tessa Buckle; Gijs H KleinJan; James C Hardwick; Henk G van der Poel; Fijs Wb van Leeuwen Journal: Am J Nucl Med Mol Imaging Date: 2017-07-15
Authors: Tessa Buckle; Danny M van Willigen; Silvia J Spa; Albertus W Hensbergen; Steffen van der Wal; Clarize M de Korne; Mick M Welling; Henk G van der Poel; James C H Hardwick; Fijs W B van Leeuwen Journal: J Nucl Med Date: 2018-02-15 Impact factor: 10.057
Authors: Thomas Horn; Markus Krönke; Isabel Rauscher; Bernhard Haller; Stephanie Robu; Hans-Jürgen Wester; Margret Schottelius; Fijs W B van Leeuwen; Henk G van der Poel; Matthias Heck; Jürgen E Gschwend; Wolfgang Weber; Matthias Eiber; Tobias Maurer Journal: Eur Urol Date: 2019-04-12 Impact factor: 20.096
Authors: Ying Chen; Mrudula Pullambhatla; Sangeeta R Banerjee; Youngjoo Byun; Marigo Stathis; Camilo Rojas; Barbara S Slusher; Ronnie C Mease; Martin G Pomper Journal: Bioconjug Chem Date: 2012-12-04 Impact factor: 4.774
Authors: Margret Schottelius; Alexander Wurzer; Katharina Wissmiller; Roswitha Beck; Maximilian Koch; Dimitrios Gorpas; Johannes Notni; Tessa Buckle; Matthias N van Oosterom; Katja Steiger; Vasilis Ntziachristos; Markus Schwaiger; Fijs W B van Leeuwen; Hans-Jürgen Wester Journal: J Nucl Med Date: 2018-09-20 Impact factor: 10.057
Authors: Gijs H KleinJan; Anton Bunschoten; Nynke S van den Berg; Renato A Valdès Olmos; W Martin C Klop; Simon Horenblas; Henk G van der Poel; Hans-Jürgen Wester; Fijs W B van Leeuwen Journal: Eur J Nucl Med Mol Imaging Date: 2016-03-28 Impact factor: 9.236
Authors: Samaneh Azargoshasb; Imke Boekestijn; Meta Roestenberg; Gijs H KleinJan; Jos A van der Hage; Henk G van der Poel; Daphne D D Rietbergen; Matthias N van Oosterom; Fijs W B van Leeuwen Journal: Mol Imaging Biol Date: 2022-06-16 Impact factor: 3.488
Authors: Tessa Buckle; Albertus W Hensbergen; Danny M van Willigen; Frank Bosse; Kevin Bauwens; Rob C M Pelger; Fijs W B van Leeuwen Journal: EJNMMI Res Date: 2021-05-29 Impact factor: 3.138
Authors: Albertus Wijnand Hensbergen; Danny M van Willigen; Florian van Beurden; Pim J van Leeuwen; Tessa Buckle; Margret Schottelius; Tobias Maurer; Hans-Jürgen Wester; Fijs W B van Leeuwen Journal: Bioconjug Chem Date: 2020-01-06 Impact factor: 4.774
Authors: Pieterjan Debie; Noemi B Declerck; Danny van Willigen; Celine M Huygen; Bieke De Sloovere; Lukasz Mateusiak; Jessica Bridoux; Janik Puttemans; Nick Devoogdt; Fijs W B van Leeuwen; Sophie Hernot Journal: Biomolecules Date: 2021-02-26
Authors: Mohammed Al-Qahtani; Martin Behe; Guy Bormans; Giuseppe Carlucci; Jean Dasilva; Clemens Decristoforo; Philip H Elsinga; Klaus Kopka; Xiang-Guo Li; Robert Mach; Oskar Middel; Jan Passchier; Marianne Patt; Ivan Penuelas; Ana Rey; Peter J H Scott; Sergio Todde; Jun Toyohara; Danielle Vugts Journal: EJNMMI Radiopharm Chem Date: 2021-01-28
Authors: Florian van Beurden; Danny M van Willigen; Borivoj Vojnovic; Matthias N van Oosterom; Oscar R Brouwer; Henk G van der Poel; Hisataka Kobayashi; Fijs W B van Leeuwen; Tessa Buckle Journal: Mol Imaging Date: 2020 Jan-Dec Impact factor: 4.488
Authors: Tessa Buckle; Steffen van der Wal; Danny M van Willigen; Germaine Aalderink; Gijs H KleinJan; Fijs W B van Leeuwen Journal: Theranostics Date: 2020-08-06 Impact factor: 11.556
Authors: Yvonne H W Derks; Mark Rijpkema; Helene I V Amatdjais-Groenen; Cato C Loeff; Kim E de Roode; Annemarie Kip; Peter Laverman; Susanne Lütje; Sandra Heskamp; Dennis W P M Löwik Journal: Bioconjug Chem Date: 2021-12-25 Impact factor: 4.774
Authors: Tobias Stemler; Caroline Hoffmann; Ina M Hierlmeier; Stephan Maus; Elmar Krause; Samer Ezziddin; Gregor Jung; Mark D Bartholomä Journal: ChemMedChem Date: 2021-05-24 Impact factor: 3.466